CDT Equity (CDT) Total Liabilities (2021 - 2026)
CDT Equity's (CDT) quarterly Total Liabilities came in at $21.6 million in Q1 2026, up 366.9% YoY from $4.6 million in Q1 2025, and up 68.77% on a QoQ basis from $12.8 million in Q4 2025.
CDT Equity (CDT) Total Liabilities (2021 - 2026) Analysis & Trends
CDT Equity (CDT) has 6 years of Total Liabilities data on file, last reported at $21.6 million in Q1 2026.
- Quarterly Total Liabilities rose 366.9% year-over-year to $21.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $21.6 million (up 366.9% YoY) and the FY2025 annual result came in at $12.8 million, up 16.69% from the prior year.
- Total Liabilities improved to $21.6 million in Q1 2026, from $12.8 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $21.6 million in Q1 2026 to a low of $4.3 million in Q3 2025.
- A 5-year average of $9.1 million and a median of $8.0 million in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities soared 5143.47% — and 2025, when it sank 64.71%.
- Tracing CDT's Total Liabilities over 5 years: stood at $10.1 million in 2022, then declined by 23.91% to $7.7 million in 2023, then jumped by 43.03% to $11.0 million in 2024, then gained by 16.69% to $12.8 million in 2025, then surged by 68.77% to $21.6 million in 2026.
- The last three Total Liabilities figures came in at $21.6 million (Q1 2026), $12.8 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | CDT Equity | 1.55 Mn | 1.55 Mn | - | 23.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.62 Mn |
| Mar 31, 2026 | 21.64 Mn |
| Dec 31, 2025 | 12.82 Mn |
| Sep 30, 2025 | 4.27 Mn |
| Jun 30, 2025 | 4.46 Mn |
| Mar 31, 2025 | 4.63 Mn |
| Dec 31, 2024 | 10.99 Mn |
| Sep 30, 2024 | 12.11 Mn |
| Jun 30, 2024 | 8.77 Mn |
| Mar 31, 2024 | 8.02 Mn |
| Dec 31, 2023 | 7.68 Mn |
| Sep 30, 2023 | 13.10 Mn |
| Jun 30, 2023 | 15.04 Mn |
| Mar 31, 2023 | 6.59 Mn |
| Dec 31, 2022 | 10.09 Mn |
| Sep 30, 2022 | 4.94 Mn |
| Jun 30, 2022 | 4.77 Mn |
| Mar 31, 2022 | 4.71 Mn |
| Dec 31, 2021 | 192,506.00 |